The popularity of copyright’s blockbuster initially fueled a boom for pharma, but recent shifts present a murky outlook for shareholders. Lower-cost competitors are eroding earnings, and ongoing litigation add more https://gregorysdzy836088.blogdosaga.com/41186903/the-blue-pill-and-the-pharmaceutical-industry-a-precarious-bet